MyOme Unveils Enhanced Genome Test to Transform Rare Disease Diagnosis
MyOme, a Menlo Park leader in clinical whole genome analysis, has announced a significant upgrade to its rare disease testing platform, now offering tandem repeat expansion (TRE) and mitochondrial genome…